Treatment of Rat Spinal Cord Injury with the Neurotrophic Factor Albumin-Oleic Acid: Translational Application for Paralysis, Spasticity and Pain
Open Access
- 26 October 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e26107
Abstract
Sensorimotor dysfunction following incomplete spinal cord injury (iSCI) is often characterized by the debilitating symptoms of paralysis, spasticity and pain, which require treatment with novel pleiotropic pharmacological agents. Previous in vitro studies suggest that Albumin (Alb) and Oleic Acid (OA) may play a role together as an endogenous neurotrophic factor. Although Alb can promote basic recovery of motor function after iSCI, the therapeutic effect of OA or Alb-OA on a known translational measure of SCI associated with symptoms of spasticity and change in nociception has not been studied. Following T9 spinal contusion injury in Wistar rats, intrathecal treatment with: i) Saline, ii) Alb (0.4 nanomoles), iii) OA (80 nanomoles), iv) Alb-Elaidic acid (0.4/80 nanomoles), or v) Alb-OA (0.4/80 nanomoles) were evaluated on basic motor function, temporal summation of noxious reflex activity, and with a new test of descending modulation of spinal activity below the SCI up to one month after injury. Albumin, OA and Alb-OA treatment inhibited nociceptive Tibialis Anterior (TA) reflex activity. Moreover Alb-OA synergistically promoted early recovery of locomotor activity to 50±10% of control and promoted de novo phasic descending inhibition of TA noxious reflex activity to 47±5% following non-invasive electrical conditioning stimulation applied above the iSCI. Spinal L4–L5 immunohistochemistry demonstrated a unique increase in serotonin fibre innervation up to 4.2±1.1 and 2.3±0.3 fold within the dorsal and ventral horn respectively with Alb-OA treatment when compared to uninjured tissue, in addition to a reduction in NR1 NMDA receptor phosphorylation and microglia reactivity. Early recovery of voluntary motor function accompanied with tonic and de novo phasic descending inhibition of nociceptive TA flexor reflex activity following Alb-OA treatment, mediated via known endogenous spinal mechanisms of action, suggests a clinical application of this novel neurotrophic factor for the treatment of paralysis, spasticity and pain.Keywords
This publication has 92 references indexed in Scilit:
- A Grading System To Evaluate Objectively the Strength of Pre-Clinical Data of Acute Neuroprotective Therapies for Clinical Translation in Spinal Cord InjuryJournal of Neurotrauma, 2011
- A Systematic Review of Directly Applied Biologic Therapies for Acute Spinal Cord InjuryJournal of Neurotrauma, 2011
- Voluntary ankle flexor activity and adaptive coactivation gain is decreased by spasticity during subacute spinal cord injuryExperimental Neurology, 2010
- Spasticity therapy reacts to astrocyte GluA1 receptor upregulation following spinal cord injuryBritish Journal of Pharmacology, 2010
- Oleic acid reduces lipopolysaccharide-induced expression of iNOS and COX-2 in BV2 murine microglial cells: Possible involvement of reactive oxygen species, p38 MAPK, and IKK/NF-κB signaling pathwaysNeuroscience Letters, 2009
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Recovery of supraspinal control of stepping via indirect propriospinal relay connections after spinal cord injuryNature Medicine, 2008
- Omega-3 Fatty Acids Improve Recovery, whereas Omega-6 Fatty Acids Worsen Outcome, after Spinal Cord Injury in the Adult RatJournal of Neuroscience, 2006
- MASCIS Evaluation of Open Field Locomotor Scores: Effects of Experience and Teamwork on ReliabilityJournal of Neurotrauma, 1996
- Postnatal Dietary Fat Influences mRNAS Involved in MyelinationDevelopmental Neuroscience, 1992